The traditional Chinese medicine sector fluctuated and surged, with GZBL hitting the limit up

The traditional Chinese medicine sector experienced a volatile surge, with GZBL hitting the limit up, and Weikang Pharmaceutical, Darentang, Fangsheng Pharmaceutical, Panlong Pharmaceutical, and Wohua Pharmaceutical following suit. In terms of related ETFs, the traditional Chinese medicine ETF had a trading volume of 15.1552 million yuan. On October 15th, GZBL announced that its subsidiary, "Bailing Yuxiu Pharmaceutical Co., Ltd.," has once again received the "Drug Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration's Drug Review Center, allowing the clinical trial of the traditional Chinese medicine Class 1 new drug, Tang Ning Tong Luo Pian, for the treatment of type 2 diabetes